Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

How to Cite

OrthoEvidence. Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates. ACE Report. 2017;6(1):48. Available from: https://myorthoevidene.com/AceReport/Report/9245

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:N/A

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Contributing Authors: PD Miller N Pannacciulli JP Brown E Czerwinski BS Nedergaard MA Bolognese J Malouf HG Bone JY Reginster A Singer C Wang RB Wagman SR Cummings

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

643 postmenopausal women with osteoporosis who had used oral bisphosphonate for a minimum of 2 years were randomized to either subcutaneous injections of denosumab 60mg - one at baseline and another at 6 months - or intravenous injection of zoledronic acid 5mg. The purpose of this study was to evaluate if denosumab offered noninferior or superior efficacy and safety to zoledronic acid for increasi...